Gritstone Oncology Reports Promising Early Immunogenicity Activity and Safety Data from its Phase 1 Studies Evaluating its Neoantigen-based Immunotherapies, GRANITE and SLATE
Gritstone bio, Inc. (GRTS)
Last gritstone bio, inc. earnings: 11/12 09:01 am
Check Earnings Report
Company Research
Source: GlobeNewswire
-- Preliminary results demonstrate unprecedented levels of primed CD8+ neoantigen-specific cytotoxic T cells and expansion of pre-existing T cells even in low-dose cohorts ---- Investor conference call and webcast at 8:00 am ET today -- EMERYVILLE, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today announced that the company has presented preliminary Phase 1 GRANITE immunogenicity data demonstrating the rapid, robust and consistent induction of large numbers of CD8+ T cells against multiple neoantigens in four solid tumor patients with available IFN-g ELISpot data (up to 3,000 IFN-g spot forming units per 106 PBMCs were generated, as measured by overnight ELISpot) within the first two dosing cohorts. Importantly, these T cells were also able to produce IL-2 and Granzyme B, demonstrating that they have cytotoxic pot
Show less
Read more
Impact Snapshot
Event Time:
GRTS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GRTS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GRTS alerts
High impacting Gritstone bio, Inc. news events
Weekly update
A roundup of the hottest topics
GRTS
News
- Gritstone bio Takes Action to Preserve Value and Strengthen Capital StructureBusiness Wire
- Gritstone bio, Inc. (NASDAQ: GRTS) was downgraded by analysts at B. Riley from a "strong-buy" rating to a "hold" rating.MarketBeat
- Gritstone bio, Inc. (NASDAQ: GRTS) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Gritstone bio, Inc. (NASDAQ: GRTS) had its "neutral" rating re-affirmed by analysts at B. Riley. They now have a $1.00 price target on the stock, down previously from $3.00.MarketBeat
- Gritstone bio, Inc. (NASDAQ: GRTS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $0.50 price target on the stock, down previously from $4.00.MarketBeat
GRTS
Earnings
- 8/13/24 - Beat
GRTS
Sec Filings
- 10/16/24 - Form 8-K
- 10/10/24 - Form 8-K
- 10/7/24 - Form SC
- GRTS's page on the SEC website